ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Engineering a chitosan-based nanoemulsion for non-invasive CNS-targeting approach: dual neuroprotection against epileptic and depressive disorders.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The frequent comorbidity of epilepsy and depression presents a major therapeutic challenge, with current therapies limited by systemic side effects and poor blood-brain barrier penetration. This study aimed to develop a non-invasive, dual-therapy topical nanoemulsion for combined (additive), rather than formally demonstrated synergistic, neuroprotection. A Quality-by-Design optimized chitosan-lipid nanoemulsion co-encapsulating ashwagandha extract and citicoline was engineered. The formulation exhibited favorable characteristics: nanoscale size (~ 145 nm), positive zeta potential (+ 35.9 mV), and sustained in vitro drug release. Its efficacy was evaluated in rat models of acute strychnine-induced seizures and forced swimming test-induced depression following topical application to the shaved head region. The treatment significantly attenuated seizure severity and latency in the acute seizure model. Concurrently, it reversed depressive-like behaviors across multiple tests (Forced Swim Test, FST; Tail Suspension Test, TST; and Sucrose Preference Test, SPT), with efficacy surpassing oral fluoxetine. Histopathological analysis of brain tissue confirmed pronounced neuroprotection in both models. This chitosan-based topical nanoemulsion presents a promising, patient-compliant strategy for dual neuroprotection against interconnected neurological disorders, offering a proof-of-concept for a novel combinatorial therapeutic approach. Although direct pharmacokinetic confirmation of brain drug distribution remains to be established, the observed pharmacodynamic and histopathological outcomes are consistent with CNS engagement following topical application, supporting further investigation of this delivery platform.
Indexed as
Identifiers
42834205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.